Business Context and Reporting Period
Inventiva S.A., a French biopharmaceutical company, filed this Form 6-K for September 2023. On September 28, 2023, the company entered into a new sales agreement with Cowen and Company, LLC, doing business as TD Cowen, for an at-the-market equity offering of American Depositary Shares (ADSs).
Key Financial and Capital Markets Information
- The new program permits sales of ADSs representing ordinary shares with aggregate gross proceeds of up to $58.0 million.
- TD Cowen will receive a commission equal to 3.0% of gross sales proceeds from ADSs sold through the program.
- Inventiva is not obligated to sell any ADSs, and TD Cowen is not required to sell a specific amount.
- The filing does not provide revenue, profit, cash flow, operating margin, debt, cash balance, or liquidity figures.
Material Changes Versus the Prior Comparable Arrangement
- Inventiva terminated its prior sales agreement with Jefferies LLC, effective September 28, 2023, after providing notice on September 22, 2023.
- The prior Jefferies program had authorized aggregate ADS sales of up to $100.0 million; $41.7 million of ADSs had been issued and sold under that agreement as of September 22, 2023.
- The new TD Cowen program has a lower maximum offering capacity of $58.0 million and replaces the Jefferies arrangement.
Guidance, Outlook, Risks, and Unusual Items
- The offering is intended to provide potential access to additional equity capital, but the timing and amount of any proceeds are uncertain because sales are discretionary and market dependent.
- Any ADS issuance would dilute existing shareholders and could pressure the market price of the ADSs.
- TD Cowen may conduct sales through at-the-market transactions or, with Inventiva’s consent, negotiated transactions.
- Either Inventiva or TD Cowen may terminate the agreement at any time with four days’ prior notice. The program also ends when all covered ADSs have been sold.
- No funds will be held in escrow, trust, or a similar arrangement.
- Inventiva agreed to indemnification and contribution obligations in favor of TD Cowen relating to certain securities-law liabilities.
Important Facts to Verify
- Whether Inventiva has sold any ADSs under the TD Cowen program and the resulting gross and net proceeds.
- The remaining availability, if any, under the $58.0 million offering authorization.
- Use of proceeds and the effect of any equity issuance on cash runway, funding needs, and shareholder dilution.
- The company’s latest cash balance, operating cash burn, debt, and financial results, which are not included in this filing.
- The complete terms of the Sales Agreement filed as Exhibit 1.1 and related legal opinion filed as Exhibit 5.1.